Oxford, UK 26 September 2011 - PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.

The first release of this monthly report on all of the top 12 pharmaceutical companies shows Pfizer has overtaken GlaxoSmithKline and are now placed second only to Roche in the industry’s new Deal Activity League Table*. The first monthly edition is available as a free download on our website (www.pharmadeals.net/corpmetrx). The ranking information and expert insight from PharmaVentures will be invaluable to analysts, M&A and corporate finance professionals in investment banks, hedge funds, large cap advisory and asset management firms as well as business development and competitive intelligence professionals, chief executives and other senior managers within pharmaceutical and biotechnology companies.

PharmaDeals® Corp-METRx provides key metrics on the relative strengths and weaknesses of the world's top 12 pharmaceutical companies, and is delivered in a concise and instantly accessible online format. This new publication, edited by PharmaVentures’ expert, Nigel Borshell, provides an essential look-up for key facts about how major pharmaceutical companies’ deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.

Anne Vindenes Allen, PharmaDeals' Executive Director, says, "The industry was in need of a report that would readily analyse how well top companies are performing as deal makers, andPharmaDeals Corp-METRx does just that. Reports on each company are available, along with our expert assessment reviewing the changes of all those 12 companies.”

Download the free first edition of PharmaDeals Corp-METRx and read the monthly review article now:

www.pharmadeals.net/corpmetrx

For further information, contact:
Anne Vindenes Allen
Executive Director, PharmaDeals
+44 1865 332700
anne.allen@pharmaventures.com

- ends -